Patients with generalized myasthenia gravis (gMG) experience significant and heterogeneous symptomatology, placing a substantial burden on their quality of life including physical, emotional, and work/financial aspects. Recent clinical trial data are showing that the utilization of individualized dosing including holding treatment during periods of stability can be effective and safe. It is important for clinicians to assess these data and individualize their treatment plans. This activity will focus on advances to optimize clinical outcomes in patients with gMG.
Neurologists, neuromuscular specialists, and other healthcare professionals involved in the treatment and management of patients with generalized myasthenia gravis
- Review the disease symptom heterogeneity of generalized myasthenia gravis and the rationale for individualized therapy to optimize outcomes through periods of waxing and waning symptom burden
- Analyze clinical trial data including real world data for the clinical applications of FcRn and complement inhibitors in the management of gMG
- Discuss the effects of individual patient and disease specifics on gMG treatment planning, dosing recommendations, and the management of symptom-free periods
- Review the impact of comorbidities on treatment goals and outcomes for patients with gMG
I. Generalized Myasthenia Gravis: The Impact of Lessons Learned on Patient Outcomes
- Characterizing Variability in the Symptom Burden for Patients with gMG
- Patient Heterogeneity Drives Individualized Treatment Plans
- Clinical Trial and Real-World Data Update and Applications for FcRn and Complement Inhibitor Therapeutics for gMG
- Practical Recommendations for Therapeutic Selection, Dosing, Route of Administration, Treatment During Periods of Stability, and Monitoring the Effects of Comorbidities
Disclosures of Relevant Financial Relationships
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships relating to the topics of this educational activity. Any relevant financial relationships are mitigated via a content review by planning committee members and faculty with no relevant financial relationships.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
|Faculty||Relationship Identified With:|
|James F. Howard Jr., MD
|Consultant/Advisor: Alexion Pharmaceuticals; argenX; Biologix Pharma; F. Hoffmann-LaRoche Ltd; Horizon Therapeutics; Immunovant; Merck Serono; NMD Pharma; Novartis Pharma; Ra Pharmaceuticals/UCB; Regeneron Pharmaceuticals; Sanofi, US; Toleranzia AB; Zai Labs
Grant/Research Support: Alexion Pharmaceuticals; argenX; Cartesian Therapeutics; The Centers for Disease Control and Prevention; Millennium Pharmaceuticals; National Institutes of Health; PCORI; Ra Pharmaceuticals/UCB
Stocks: General Electric; GlaxoSmithKline; GE Healthcare; Johnson & Johnson Services, Inc.; Pfizer; Viatris
Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Nicole McMenamin and Chelsey Simonds hereby state that they or their spouse/life partner do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM.
Physcians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by an independent educational grant from argenX.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and argenX do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Learners who receive a grade of 60% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
- CME and CNE credit will be issued appropriate certificate of completion.
- Others may request a “certificate of completion”.
- Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].